Trials / Terminated
TerminatedNCT04547985
Naltrexone Treatment for Prolonged Grief Disorder (PGD)
Naltrexone Treatment for Prolonged Grief Disorder: A Pilot Study
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Weill Medical College of Cornell University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naltrexone HCl 50 MG Oral Tablet | Generic, oral tablet. |
| DRUG | Placebo | Composed of filler material and encapsulated to appear identical to naltrexone. |
Timeline
- Start date
- 2021-01-05
- Primary completion
- 2023-10-16
- Completion
- 2023-10-16
- First posted
- 2020-09-14
- Last updated
- 2024-08-28
- Results posted
- 2024-08-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04547985. Inclusion in this directory is not an endorsement.